| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $138,125,950 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS136272 | Harnessing engineered drug-free polymeric nanoformulations to reprogram innate immune cells for spinal trauma | 000 | 3 | NIH | 3/3/2026 | $326,594 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P01AG078116 | Strategies for targeting astrocyte reactivity in Alzheimer's disease and related dementias | 000 | 5 | NIH | 7/3/2026 | $3,985,231 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25AG092311 | Kentucky Postbaccalaureate Alzheimer’s Disease Research Education Program (KYPAD) | 000 | 2 | NIH | 6/18/2026 | $418,309 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD116429 | The role of glucocorticoid receptor in the ovary | 000 | 2 | NIH | 5/28/2026 | $643,408 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA033862 | Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian Cohorts | 000 | 12 | NIH | 1/29/2026 | $482,290 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA301113 | Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer | 000 | 2 | NIH | 4/2/2026 | $215,985 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 001 | 3 | NIH | 2/26/2026 | $65,020 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 000 | 3 | NIH | 1/19/2026 | $585,180 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P50MD019476 | UK ASCEND (Achieving Success in Community-Engaged research to elimiNate Disparities) | 001 | 3 | NIH | 7/23/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P50MD019476 | UK ASCEND (Achieving Success in Community-Engaged research to elimiNate Disparities) | 000 | 3 | NIH | 6/1/2026 | $598,149 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 000 | 3 | NIH | 2/27/2026 | $402,968 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 001 | 12 | NIH | 3/19/2026 | $464,493 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG081608 | Molecular genetics of human age-related hearing loss | 001 | 4 | NIH | 3/10/2026 | $587,270 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P30AG072946 | University of Kentucky Alzheimer's Disease Research Center | 000 | 6 | NIH | 8/28/2026 | $4,404,400 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32AA027488 | Interdisciplinary Training in Alcohol Research | 000 | 8 | NIH | 4/21/2026 | $172,616 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 003 | 12 | NIH | 8/27/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 002 | 12 | NIH | 4/27/2026 | $146,682 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084850 | Regulation of Myonuclear Turnover Dynamics in Multinucleated Muscle Cells | 000 | 2 | NIH | 6/12/2026 | $529,010 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG092253 | Feasibility, Acceptability, and Preliminary Efficacy of an HIV Prevention Intervention for Older Black Women | 000 | 2 | NIH | 8/18/2026 | $126,015 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140148 | Role of Hypothalamic Adgrl1 in Counteracting Hypoglycemia | 000 | 2 | NIH | 4/13/2026 | $480,373 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25CA302429 | Markey STRONG Scholars Program | 000 | 2 | NIH | 6/19/2026 | $223,823 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS138293 | Function of sphingoid bases in brain health and disease | 000 | 2 | NIH | 6/11/2026 | $377,030 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30NS141486 | Fellowship for Annabel McAtee: Elucidating the role of the dura mater in the post-stroke B cell response | 000 | 2 | NIH | 8/26/2026 | $43,714 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 001 | 2 | NIH | 4/27/2026 | $2,048 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 000 | 2 | NIH | 4/3/2026 | $522,854 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD116735 | Harnessing the inflammatory response to promote regeneration in mammals | 000 | 2 | NIH | 4/27/2026 | $657,560 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES030380 | Radon on the RADAR | 001 | 8 | NIH | 5/26/2026 | $514,461 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32DK138894 | Diabetes and ObesitY research training in kENtucky (DOYEN) | 000 | 2 | NIH | 7/28/2026 | $175,412 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS122028 | Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease | 001 | 3 | NIH | 3/5/2026 | $58,999 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS122028 | Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease | 000 | 3 | NIH | 1/30/2026 | $530,998 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00DA056288 | Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities | 000 | 5 | NIH | 3/19/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DE035485 | Baculovirus-Based Minimally Invasive Therapy for Head and Neck Squamous Cell Carcinoma | 000 | 1 | NIH | 8/10/2026 | $591,176 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA308383 | Implementing Population-level Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Hazardous Alcohol Use in Routine Cancer Care as a Novel Means of Secondary Cancer Risk Reduction | 000 | 1 | NIH | 8/5/2026 | $610,625 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32AI192234 | Transdisciplinary Training in Microbiology & Immunology | 000 | 1 | NIH | 8/10/2026 | $144,825 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AA032581 | Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Action on Neurotransmission in the Extended Amygdala During Alcohol-Abstinence | 000 | 1 | NIH | 8/21/2026 | $536,524 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA296401 | Rewired Lipid Metabolism Upon Spermine Synthase Inhibition In Colorectal Cancer Tumorigenesis | 000 | 1 | NIH | 8/20/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA316685 | AI-Enhanced Methods for Cancer Surveillance: Improving Automated Information Extraction with DAC for Clinically Actionable Cancer Types | 000 | 1 | NIH | 8/11/2026 | $492,482 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL181997 | Developmental Programming of Cardiovascular Disease due to Prenatal Fentanyl Exposure | 000 | 1 | NIH | 8/10/2026 | $642,211 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | UM1TR006383 | Kentucky Center for Clinical and Translational Science | 000 | 1 | NIH | 9/3/2026 | $4,004,255 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA064086 | Opioid Use Disorder County Area Prevalence Through Use of Recapture Estimates (OUD CAPTURE) | 000 | 1 | NIH | 8/31/2026 | $548,992 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086367 | Nutrient sensing and cell fate determination through structural allostery in PASK | 000 | 1 | NIH | 9/1/2026 | $294,652 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR086367 | Nutrient sensing and cell fate determination through structural allostery in PASK | 000 | 1 | NIH | 9/1/2026 | $350,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K99NS150925 | Clinical Prediction, Genetic Architecture, and Environmental Modification in Alzheimer’s Disease, LATE, and Mixed Pathology | 000 | 1 | NIH | 9/3/2026 | $124,945 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084134 | Biomarkers to Track Effective Interventions that Delay Dementia Onset in Participants of the "Risk Reduction for Alzheimer's Disease (rrAD)" Trial | 000 | 2 | NIH | 8/31/2026 | $742,367 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL177556 | Targeting NINJ1-mediated Plasma Membrane Rupture to Prevent Thrombosis | 000 | 2 | NIH | 8/7/2026 | $528,032 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS147149 | Repetitive Mild TBI and Physiological Stress as Catalysts for Chronic Neurovascular Dysfunction | 000 | 1 | NIH | 1/26/2026 | $192,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03CA308625 | Fatty Acid Synthase Driven Exosome Secretion in Colorectal Cancer Metastasis | 000 | 1 | NIH | 6/9/2026 | $154,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG093616 | Evaluation of Noninvasive Muscle Imaging Biomarkers for Knee Osteoarthritis in Older Adults | 000 | 1 | NIH | 1/23/2026 | $666,504 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140312 | Targeting Intracellular Cholesterol Distribution: Mechanisms and Therapeutic Strategies for Metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/11/2026 | $707,062 |
|
